Akebia Therapeutics logo

Akebia Therapeutics share price today

(AKBA)

Akebia Therapeutics share price is $1.86 & ₹158.47 as on 25 Dec 2024, 2.30 'hrs' IST

$1.86

0.01

(0.54%)

Market is closed - opens 8 PM, 26 Dec 2024

View live Akebia Therapeutics share price in Dollar and Rupees. Guide to invest in Akebia Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Akebia Therapeutics. Get details on the Indian mutual funds that are investing in Akebia Therapeutics. Get Analyst recommendations and forecasts along with all the Akebia Therapeutics's financials.

Akebia Therapeutics share price movements

  • Today's Low: $1.83
    Today's High: $1.88

    Day's Volatility :2.66%

  • 52 Weeks Low: $0.80
    52 Weeks High: $2.48

    52 Weeks Volatility :67.74%

Akebia Therapeutics Returns

PeriodAkebia Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
39.85%
-9.0%
0.0%
6 Months
88.03%
-4.6%
0.0%
1 Year
55.0%
3.0%
0.0%
3 Years
-22.5%
0.0%
-21.1%

Akebia Therapeutics Key Statistics

in dollars & INR

Previous Close
$1.85
Open
$1.86
Today's High
$1.88
Today's Low
$1.83
Market Capitalization
$405.8M
Today's Volume
$511.5K
52 Week High
$2.48
52 Week Low
$0.8
Revenue TTM
$169.9M
EBITDA
$4.4M
Earnings Per Share (EPS)
$-0.22
Profit Margin
-27.07%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-553.45%

How to invest in Akebia Therapeutics from India?

It is very easy for Indian residents to invest directly in Akebia Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Akebia Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Akebia Therapeutics or AKBA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Akebia Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Akebia Therapeutics shares which would translate to 0.458 fractional shares of Akebia Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Akebia Therapeutics, in just a few clicks!

Returns in Akebia Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Akebia Therapeutics investment value today

Current value as on today

₹1,57,239

Returns

₹57,239

(+57.24%)

Returns from Akebia Therapeutics Stock

₹55,000 (+55%)

Dollar Returns

₹2,239 (+2.24%)

Indian investors sentiment towards Akebia Therapeutics

56%

Period: Sep 26, 2024 to Dec 25, 2024. Change in 30 Days versus previous period

Search volume for Akebia Therapeutics on INDmoney from India has grown in the last 30 days as on Dec 26, 2024. 56% more investors are searching Akebia Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Akebia Therapeutics

  • BlackRock Inc

    5.33%

  • Vanguard Group Inc

    4.62%

  • SATTER MANAGEMENT CO., L.P.

    2.63%

  • Geode Capital Management, LLC

    2.18%

  • Renaissance Technologies Corp

    1.70%

  • State Street Corp

    1.57%

Analyst Recommendation on Akebia Therapeutics

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Akebia Therapeutics(by analysts ranked 0 to 5 stars)

Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Akebia Therapeutics

What analysts predicted

Upside of 195.7%

Current:

$1.86

Target:

$5.50

Insights on Akebia Therapeutics

  • Price Movement

    In the last 3 months, AKBA stock has moved up by 39.8%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 43.64M → 37.42M (in $), with an average decrease of 14.3% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.58M → -20.03M (in $), with an average decrease of 133.5% per quarter

Akebia Therapeutics Technicals Summary

Sell

Neutral

Buy

Akebia Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Akebia Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akebia Therapeutics Inc
-9.27%
88.03%
55.0%
-22.5%
-71.73%
Neurocrine Biosciences Inc.
6.74%
1.65%
2.84%
61.59%
27.41%
Haleon Plc Spon Ads
1.56%
15.54%
17.63%
31.44%
31.44%
Zoetis Inc.
-6.26%
-6.66%
-16.35%
-33.19%
24.57%
Viatris Inc.
-5.2%
18.32%
15.13%
-9.29%
-24.11%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akebia Therapeutics Inc
NA
NA
0.0
-0.26
-5.53
-0.09
NA
-0.24
Neurocrine Biosciences Inc.
36.41
36.41
0.32
6.37
0.16
0.12
NA
26.87
Haleon Plc Spon Ads
29.52
29.52
1.76
0.34
0.07
0.04
0.02
1.82
Zoetis Inc.
30.96
30.96
2.56
5.88
0.47
0.15
0.01
11.59
Viatris Inc.
224.4
NA
0.07
2.69
-0.04
0.02
0.04
16.58
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akebia Therapeutics Inc
Buy
$405.8M
-71.73%
NA
-27.07%
Neurocrine Biosciences Inc.
Buy
$13.8B
27.41%
36.41
17.21%
Haleon Plc Spon Ads
Buy
$44.0B
31.44%
29.52
10.75%
Zoetis Inc.
Buy
$74.3B
24.57%
30.96
26.55%
Viatris Inc.
Hold
$14.8B
-24.11%
224.4
-5.87%

About Akebia Therapeutics

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Organization
Akebia Therapeutics
Employees
167
CEO
Mr. John P. Butler MBA
Industry
Health Technology

Management People of Akebia Therapeutics

NameTitle
Mr. John P. Butler MBA
CEO, President & Director
Dr. Steven Keith Burke M.D.
Senior VP of Research & Development and Chief Medical Officer
Mr. Erik John Ostrowski M.B.A.
Senior VP, CFO & Chief Business Officer
Mr. Richard C. Malabre
Chief Accounting Officer
Ms. Kimberly Garko
Senior VP & Chief Technical Officer
Ms. Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration
Mercedes Carrasco
Senior Director of Investor & Corporate Communications
Ms. Carolyn Rucci
Senior VP of Legal, General Counsel & Secretary
Ms. Meredith Bowman
Senior VP & Chief People Officer
Mr. Nicholas Grund
Senior VP & Chief Commercial Officer

Important FAQs about investing in Akebia Therapeutics from India :

What is Akebia Therapeutics share price today?

Akebia Therapeutics share price today stands at $1.86, Open: $1.86 ; Previous Close: $1.85 ; High: $1.88 ; Low: $1.83 ; 52 Week High: $2.48 ; 52 Week Low: $0.80. The stock opens at $1.86, after a previous close of $1.85. The stock reached a daily high of $1.88 and a low of $1.83, with a 52-week high of $2.48 and a 52-week low of $0.80.

Can Indians buy Akebia Therapeutics shares?

Yes, Indians can invest in the Akebia Therapeutics (AKBA) from India.

With INDmoney, you can buy Akebia Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Akebia Therapeutics at zero transaction cost.

How can I buy Akebia Therapeutics shares from India?

It is very easy to buy Akebia Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Akebia Therapeutics be purchased?

Yes, you can buy fractional shares of Akebia Therapeutics with INDmoney app.

What are the documents required to start investing in Akebia Therapeutics stocks?

To start investing in Akebia Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Akebia Therapeutics

Today’s highest price of Akebia Therapeutics (AKBA) is $1.88.

Today’s lowest price of Akebia Therapeutics (AKBA) is $1.83.

What is today's market capitalisation of Akebia Therapeutics

Today's market capitalisation of Akebia Therapeutics AKBA is 405.8M

What is the 52 Week High and Low Range of Akebia Therapeutics

  • 52 Week High

    $2.48

  • 52 Week Low

    $0.80

What are the historical returns of Akebia Therapeutics?

  • 1 Month Returns

    -9.27%

  • 3 Months Returns

    88.03%

  • 1 Year Returns

    55%

  • 5 Years Returns

    -71.73%

Who is the Chief Executive Officer (CEO) of Akebia Therapeutics

Mr. John P. Butler MBA is the current Chief Executive Officer (CEO) of Akebia Therapeutics.